[go: up one dir, main page]

WO2003103675A3 - COMBINATION THERAPIES FOR PURINOCEPTOR RELATED DISORDERS - Google Patents

COMBINATION THERAPIES FOR PURINOCEPTOR RELATED DISORDERS Download PDF

Info

Publication number
WO2003103675A3
WO2003103675A3 PCT/US2003/017964 US0317964W WO03103675A3 WO 2003103675 A3 WO2003103675 A3 WO 2003103675A3 US 0317964 W US0317964 W US 0317964W WO 03103675 A3 WO03103675 A3 WO 03103675A3
Authority
WO
WIPO (PCT)
Prior art keywords
purinoceptor
related disorders
combination therapies
purinoceptors
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/017964
Other languages
French (fr)
Other versions
WO2003103675A2 (en
Inventor
Constance N Wilson
Mark A Sirgo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endacea Inc
Original Assignee
Endacea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endacea Inc filed Critical Endacea Inc
Priority to AU2003237460A priority Critical patent/AU2003237460A1/en
Publication of WO2003103675A2 publication Critical patent/WO2003103675A2/en
Publication of WO2003103675A3 publication Critical patent/WO2003103675A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des méthodes de prévention et de traitement des troubles liés aux récepteurs purinergiques (purinocepteurs) qui consistent à administrer en parallèle un antagoniste du récepteur d'adénosine A1 et un antagoniste du purinocepteur P2x avec au moins un autre agent actif supplémentaire efficace pour traiter les troubles liés aux purinocepteurs. Cette invention concerne également des formulations pharmaceutiques appropriées pour prévenir et pour traiter les troubles liés aux purinocepteurs.The present invention relates to methods of preventing and treating purinergic receptor (purinoceptor) disorders which involve administering in parallel an adenosine A1 receptor antagonist and a P2x purinoceptor antagonist with at least one other additional active agent effective for treat disorders related to purinoceptors. The invention also relates to pharmaceutical formulations suitable for preventing and treating disorders associated with purinoceptors.

PCT/US2003/017964 2002-06-06 2003-06-06 Combination treatments for purinoceptor-related disorders Ceased WO2003103675A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003237460A AU2003237460A1 (en) 2002-06-06 2003-06-06 Combination treatments for purinoceptor-related disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60/386,769 2002-06-06
US38676902P 2002-06-07 2002-06-07

Publications (2)

Publication Number Publication Date
WO2003103675A2 WO2003103675A2 (en) 2003-12-18
WO2003103675A3 true WO2003103675A3 (en) 2004-03-25

Family

ID=29736207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/017964 Ceased WO2003103675A2 (en) 2002-06-06 2003-06-06 Combination treatments for purinoceptor-related disorders

Country Status (2)

Country Link
AU (1) AU2003237460A1 (en)
WO (1) WO2003103675A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522916B2 (en) 2007-12-21 2016-12-20 Constance Neely Wilson A1 adenosine receptor antagonists

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009343A2 (en) * 2003-06-06 2005-02-03 Endacea, Inc. A1 adenosine receptor antogonists
WO2004110379A2 (en) * 2003-06-09 2004-12-23 Endacea, Inc. A1 adenosine receptor antagonists
ES2223287B1 (en) * 2003-08-04 2006-04-16 Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea COMPOUNDS FOR THE TREATMENT OF DEMIELINIZING AND AUTOIMMUNE DISEASES.
US20070149555A1 (en) * 2004-03-30 2007-06-28 Kyowa Hakko Kogyo Co., Ltd Prophylatic and/or therapeutic agents for chronic musculoskeletal pain
WO2011094208A2 (en) * 2010-01-26 2011-08-04 Endacea, Inc. Methods and pharmaceutical compositions for preventing and treating renal impairment
IT202000015817A1 (en) * 2020-07-01 2022-01-01 Giampietro Iachettini ADENOSINE FOR USE IN THE TREATMENT OF VIRAL INFECTIONS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026728A1 (en) * 1994-03-30 1995-10-12 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
WO1999034803A1 (en) * 1998-01-09 1999-07-15 The Trustees Of The University Of Pennsylvania Compositions and methods for use in ischemia-reperfusion and endotoxin-related tissue injury
WO1999038532A2 (en) * 1998-01-28 1999-08-05 Link Technology, Inc. Methods for the prevention and treatment of fibrosis and sclerosis
WO2002094317A1 (en) * 2001-05-18 2002-11-28 Endacea Inc. Methods and formulations of using a1 adenosine and p2x purinoreceptor antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026728A1 (en) * 1994-03-30 1995-10-12 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
WO1999034803A1 (en) * 1998-01-09 1999-07-15 The Trustees Of The University Of Pennsylvania Compositions and methods for use in ischemia-reperfusion and endotoxin-related tissue injury
WO1999038532A2 (en) * 1998-01-28 1999-08-05 Link Technology, Inc. Methods for the prevention and treatment of fibrosis and sclerosis
WO2002094317A1 (en) * 2001-05-18 2002-11-28 Endacea Inc. Methods and formulations of using a1 adenosine and p2x purinoreceptor antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NEELY C ET AL: "A1 adenosine receptor antagonist, 8-benzyl-7,(2-(ethyl(2-hydroxyethyl )amino)-ethyl)theophylline, and/or the P2X purinoceptor antagonist, pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid block endotoxin-induced lung injury.", DRUG DEVELOPMENT RESEARCH, vol. 43, no. 1, January 1998 (1998-01-01), 6th International Symposium on Adenosine and Adenine Nucleotides: New Frontiers in the 3rd Millennium;Ferrara, Italy; May 19-24, 1998, pages 76, XP009016775, ISSN: 0272-4391 *
NEELY CONSTANCE F ET AL: "A-1 adenosine receptor antagonists block ischemia-reperfusion injury of the heart.", CIRCULATION, vol. 94, no. 9 SUPPL., 1996, pages II376 - II380, XP009017123, ISSN: 0009-7322 *
NEELY CONSTANCE F ET AL: "A-1-adenosine receptor antagonists block endotoxin-induced lung injury.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 272, no. 2 PART 1, 1997, pages L353 - L361, XP000901722, ISSN: 0002-9513 *
STEINMETZ M ET AL: "Influence of purinoceptor antagonism on diadenosine pentaphosphate-induced hypotension in anesthetized rats.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. UNITED STATES SEP 2000, vol. 294, no. 3, September 2000 (2000-09-01), pages 963 - 968, XP001154546, ISSN: 0022-3565 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522916B2 (en) 2007-12-21 2016-12-20 Constance Neely Wilson A1 adenosine receptor antagonists

Also Published As

Publication number Publication date
AU2003237460A1 (en) 2003-12-22
WO2003103675A2 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
Langan et al. Talampanel, a new antiepileptic drug: single‐and multiple‐dose pharmacokinetics and initial 1‐week experience in patients with chronic intractable epilepsy
EP1478371A4 (en) METHODS AND PRODUCTS FOR ENHANCING IMMUNE RESPONSES USING IMIDAZOQUINOLINE COMPOUND
BRPI0414435A (en) methods and reagents for the treatment of immunoinflammatory disorders
WO2008002933A3 (en) Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
BRPI0414876A (en) pharmaceutical compounds and compositions for the prevention of overdose or abuse and their uses
TW200731968A (en) Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
EP2331095A4 (en) CERTAIN KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
DE60035870D1 (en) COMBINATION THERAPY FOR WEIGHT REDUCTION AND FAT TREATMENT TREATMENT
FR13C0062I2 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR TREATING NEUROLOGICAL DISORDERS
WO2005020972A3 (en) Combination therapy for the treatment of ocular neovascular disorders
MA29766B1 (en) ASSOCIATION OF A LONG-ACTING HYPNOTIC AGENT AND A SHORT-ACTING HYPNOTIC AGENT AND ITS THERAPEUTIC APPLICATION
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
WO2003103675A3 (en) COMBINATION THERAPIES FOR PURINOCEPTOR RELATED DISORDERS
HUT71331A (en) Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
EA200001010A1 (en) APPLICATION OF DEXMEDETOMIDINE FOR SEDATIVE IMPACT IN THE DEPARTMENT OF INTENSIVE THERAPY
WO2004110392A3 (en) Compositions and methods for treating coronavirus infection and sars
GB9930075D0 (en) Medicaments
EA200400394A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETIC neuropathy
WO2004089283A3 (en) Compositions and methods for treating viral infections
BR0005319A (en) Combined treatment for depression and anxiety
TNSN05130A1 (en) Synergistic combination compresing roflumilas and (r.r) -formoterol
DE60008589D1 (en) COMPOSITIONS OF ADENOSINE A1 AGONISTS WITH 5HT1 AGONISTS
WO2001045714A3 (en) Formulations of adenosine a1 agonists
AR018825A1 (en) ANTIGONISTS OF THE NON-PEPTIDIC BRADIQUININE RECEPTOR FOR USE IN THE TREATMENT OF DISORDERS AND OPHTHALMIC DISEASES
BRPI0407574A (en) pharmaceutical combinations comprising a nos inhibitor and an nmda receptor antagonist

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP